Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma

被引:18
作者
Matrone, Antonio [1 ]
Gambale, Carla [1 ]
Prete, Alessandro [1 ]
Piaggi, Paolo [2 ,3 ]
Cappagli, Virginia [1 ]
Bottici, Valeria [1 ]
Romei, Cristina [1 ]
Ciampi, Raffaele [1 ]
Torregrossa, Liborio [4 ]
De Napoli, Luigi [5 ]
Molinaro, Eleonora [1 ]
Materazzi, Gabriele [5 ]
Basolo, Fulvio [4 ]
Elisei, Rossella [1 ]
机构
[1] Univ Hosp Pisa, Dept Clin & Expt Med, Endocrine Unit, Via Paradisa 2, I-56124 Pisa, Italy
[2] Natl Inst Diabet & Digest & Kidney Dis, NIH, Phoenix, AZ 85016 USA
[3] Univ Pisa, Dept Informat Engn, I-56124 Pisa, Italy
[4] Univ Hosp Pisa, Dept Surg Med Mol Pathol & Crit Area, I-56124 Pisa, Italy
[5] Univ Hosp Pisa, Dept Surg Med Mol Pathol & Crit Area, Unit Endocrine Surg, I-56124 Pisa, Italy
关键词
medullary thyroid carcinoma; sporadic; age; distant metastasis; death rate; PROGNOSTIC-FACTORS; RET PROTOONCOGENE; CANCER; MUTATIONS; SURVIVAL; CARRIERS; HEALTH; MEN;
D O I
10.3390/cancers13010094
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The clinical behavior of medullary thyroid carcinoma is heterogeneous and can be influenced by several clinical, biochemical and molecular factors. The role of age as a prognostic factor remains controversial. In our cohort of 432 sporadic medullary thyroid carcinoma, no differences in histologic features at diagnosis and in number and type of therapies performed during the follow-up were detected when dividing the patients according to age (< and >= 65 years). Younger patients had a longer follow-up and survival time, compared to the older patients. However, in dead patients, no differences in the aggressiveness of the disease at presentation and treatments performed during the follow-up were found between the two age groups. Sporadic medullary thyroid carcinoma (MTC) is a rare malignancy with a heterogeneous clinical course. Several potential prognostic factors have been investigated, but the impact of some of these is controversial, such as age at diagnosis. We evaluated the data of 432 sporadic MTC patients followed-up for a median of 7.4 years. Patients were divided and compared according to their age at diagnosis in group A (<65 years-n = 338, 78.2%) and group B (>= 65 years-n = 94, 21.8%). No differences were detected between the two groups. Median follow-up time was significantly longer in patients <65 than >= 65 years. We observed 41 (9.5%) cancer-related death events. The death rate was similar between the two age groups. However, the Kaplan Meier curve showed a longer survival time for younger patients compared to older patients [HR 2.5 (CI 95%: 1.27-4.94), p < 0.01]. Nevertheless, no differences in the aggressiveness of the disease at presentation and in the number and type of treatments performed were found in the two subgroups of dead patients. In patients with sporadic MTC, age at diagnosis did not correlate with any clinical and pathological features. Cancer-related death events are similar in older and younger patients, but survival time is longer in the younger.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [31] Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma
    Grubbs, Elizabeth G.
    Williams, Michelle D.
    Scheet, Paul
    Vattathil, Selina
    Perrier, Nancy D.
    Lee, Jeffrey E.
    Gagel, Robert F.
    Hai, Tao
    Feng, Lei
    Cabanillas, Maria E.
    Cote, Gilbert J.
    THYROID, 2016, 26 (11) : 1553 - 1562
  • [32] Apatinib-treated advanced medullary thyroid carcinoma: a case report
    Chen, Kan
    Gao, Yun
    Shi, Fei
    Cao, Guangqiang
    Bao, Jiandong
    ONCOTARGETS AND THERAPY, 2018, 11 : 459 - 463
  • [33] C-cell hyperplasia in sporadic and familial medullary thyroid carcinoma
    Yadav, Mahima
    Agrawal, Vinita
    Pani, Krushna Chandra
    Verma, Ritu
    Jaiswal, Sushila
    Mishra, Anjali
    Pandey, Rakesh
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2018, 61 (04) : 485 - 488
  • [34] Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma
    Qu, Ning
    Shi, Xiao
    Zhao, Jing-Jing
    Guan, Haixia
    Zhang, Ting-Ting
    Wen, Shi-Shuai
    Liao, Tian
    Hu, Jia-Qian
    Liu, Wei-Yan
    Wang, Yu-Long
    Huang, Shenglin
    Shi, Rong-Liang
    Wang, Yu
    Ji, Qing-Hai
    THYROID, 2020, 30 (07) : 1025 - 1036
  • [35] Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
    Skalniak, Anna
    Trofimiuk-Muldner, Malgorzata
    Przybylik-Mazurek, Elwira
    Hubalewska-Dydejczyk, Alicja
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [36] RET protooncogene mutations in patients with apparently sporadic medullary thyroid carcinoma
    Huang, CN
    Wu, SL
    Chang, TC
    Huang, SH
    Chang, TJ
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1998, 97 (08) : 541 - 546
  • [37] Updates in the advances of sporadic medullary thyroid carcinoma: from the molecules to the clinic
    Bai, Yanhua
    Niu, Dongfeng
    Yao, Qian
    Lin, Dongmei
    Kakudo, Kennichi
    GLAND SURGERY, 2020, 9 (05) : 1847 - 1856
  • [38] The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma
    Prete, Alessandro
    Torregrossa, Liborio
    Gambale, Carla
    Ciampi, Raffaele
    Ramone, Teresa
    Romei, Cristina
    Cappagli, Virginia
    Piaggi, Paolo
    Ugolini, Clara
    Materazzi, Gabriele
    Elisei, Rossella
    Matrone, Antonio
    THYROID, 2025, : 387 - 396
  • [39] Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
    Matrone, Antonio
    Gambale, Carla
    Prete, Alessandro
    Elisei, Rossella
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [40] Sporadic Medullary Thyroid Carcinoma with Paraneoplastic Cushing Syndrome
    Pivovarova, Aleksandra I.
    Patrick, Stephanie
    Reddy, Punuru J.
    CASE REPORTS IN ENDOCRINOLOGY, 2019, 2019